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Abstract
Background: Hepatitis B is a liver disease primarily caused by hepatitis B virus (HBV) infection. It is distributed
worldwide and associated with high mortality and morbidity rates. HBV infections can be avoided by the
administration of the currently available vaccine and can be easily diagnosed through commercially available kits.
Both the vaccine and the diagnostic kits depend on using the hepatitis B surface antigen (HBsAg) as an antigen.
Developing countries such as, Egypt, suffer from the widespread of HBV infections and the limited resources to
provide adequate supplies of either the vaccine or the diagnostic kits. Therefore the need for an easy, rapid, low
cost method to produce HBsAg is urgently needed within this setting.
Findings: To achieve this goal, the gene encoding the HBsAg(S) protein was cloned and expressed as a fusion
protein with a GST tag in Escherichia coli. The recombinant protein was successfully expressed and purified in both
good quality and quantity.
Conclusions: The simplified and the relatively low cost of the used protocol make this an attractive alternative to
protocols currently used for the purification of HBsAg(S). The exploiting of this achievement for new diagnostics
can be directed for application in the developing countries where they are extremely needed.
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Background
Hepatitis B disease is a widely spread disease; it is esti-
mated that approximately 2 billion people (one third of
the world’s population) have serological evidence of past
or present HBV infection, and more than 350 million
people are chronically infected [1]. It is highly endemic
in developing regions with large population such as
South East Asia, China, Sub-Saharan Africa and the
Amazon basin, where at least 8% of the population are
HBV chronic carriers [2].
The env gene of HBV codes for three related proteins:
(1) S protein (HBsAg(S)), a 226 amino acids protein
identified as a major protein constituent of the HBV
envelope; (2) a ‘middle’ protein carrying 55 amino acids
at the N-terminus encoded by the pre-S2 portion of the
pre-S region; (3) and a ‘large’ protein encoded by the
whole ORF (pre-S1, pre-S2 and S, 389aa). The latter 2
proteins represent the minor component of HBV
envelop [3,4]. Among the three proteins, HBsAg(S) has
the highest density of epitopes against HBsAb [5].
HBsAg has been used for a long time as a vaccine
candidate and as a diagnostic immunoassay component.
In early 1980s, plasma collected from chronic HBsAg
carriers was used as a source of HBsAg. However, this
came with bio safety concerns and required rigorous
heat or chemical inactivation processes. However upon
the development of recombinant DNA techniques
HBsAg was expressed and purified in different systems
both eukaryotic and prokaryotic one [6].
The methods that are currently used to purify HBsAg
are either very costly, due to the requirement of using
immunoaffinity purifications steps, or time consuming
which would add also to the overall cost upon large
scale application [7]. In developing countries (like
Egypt), where financial resources are limited and HBV
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infections are prevalent [8,9], finding a rapid, low cost
method for production of HBsAg is of an urgent need.
In this study, we describe the expression and the purifi-
cation of a recombinant HBsAg(S) as a GST fusion pro-
tein from Escherichia coli using a simple, low cost
protocol.
Materials and methods
Bacterial strains, plasmids and growth condition
Escherichia coli strains DH5a, and DB3.1 were used for
the cloning and expression experiments. E. coli was reg-
ularly grown in either Luria Broth (LB) or Nutrient
Broth (NB) at 37°C with shaking at 180 rpm or on
media solidified with 1.5% wt/vol agar. When appropri-
ate the media were supplemented with ampicillin in a
final concentration of 100 μg/ml or kanamycin in a final
concentration of 25 μg/ml.
The commercially available vector pRc/CMV-HBs(S)
(Aldevron, USA) (Figure 1A) was used as a source for the
S gene encoding the HBsAg(S). This vector is 5618 bp and
carries the HBsAg(s) gene downstream of the CMV
immediate-early promoter for expression in mammalian
cells. In addition the plasmid carries the HBV-3’-UTR
which was found essential for the production of protein in
bacterial and mammalian cells. The selection marker on
this vector is a b-lactamase gene that confers ampicillin
resistant phenotype. For replication in prokaryotic cells,
the plasmid contains the pBR322 origin of replication [10].
The expression vector pRP265 (NCCB, Netherlands)
(Figure 1B) was chosen to express the gene encoding the
S gene as a fusion protein in E. coli. This vector is a gen-
eral cloning vector for recombinant protein production
and it depends on cloning of the gene of interest in a
polylinker site to form a fusion protein with Glutathione-
s-transferase (GST) under the control of tac promoter.
The tac promoter is a hybrid promoter derived from
sequences of the trp and the lac UV5 promoters allowing
more efficient controlled expression of foreign genes at
high levels in E. coli [11]. It encodes Amp resistance gene
as marker, LacI protein as inhibitor for the tac promoter
and a polylinker sequence with the following restriction
enzymes sites; HindIII, AccI, BamHI, EcoRI, KpnI, NcoI,
NsiI, SalI, SmaI, and SpeI. The region between the gene
encoding the GST-tag and the polylinker site contains a
thrombin recognition site for subsequent removal of the
GST-tag if needed. This vector replicates in E. coli
through its pBR322 origin of replication.
Plasmid DNA was either purchased from the produ-
cing company or purified using QIAprep Miniprep Kit
(Qiagen, USA) according to the manufacturer protocol.
Primers design for cloning of the S gene
DNA primers for PCR amplification of S gene and the
3’-UTR were designed to clone the desired fragment in
the KpnI and EcoRI sites of pRP265 due to the
absence of these two sites within the sequence of
desired piece of DNA. Primer MS-1 (5’-tgGGTACCa-
cATGGAGAACATCACATCAGGAT-3 ’, KpnI site
underlined) contained the first 22 nucleotides of the S
gene and two extra nucleotides were added between
the translational start codon (ATG) and the KpnI site
Figure 1 Diagrammatic maps of the important plasmids used
in this study. (A) Map of the pRc/CMV-HBs(S) vector that is used as
a source of the S gene of HBV. MS-1 & MS-2 indicate the positions
of the primers used to amplify the S gene and the HBV-3’-UTR. (B)
Diagrammatic map of the pRP265 vector used for cloning and
expression the HBV S gene. The insert is showing the DNA and
amino acid sequence of the multi cloning site (MCS) where the
insert will be cloned. The maps in this figure were generated using
the BioEdit software (Ibis Biosciences, USA).
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(underlined) in order to keep the S gene in frame with
the gene encoding the GST-tag. Also two additional
nucleotides were added upstream of the KpnI site to
increase the efficiency of the cleavage by the restriction
enzyme. Primer MS-2 (5’-gGAATTCCGA-
GATCCTCGCCGTCGGGCAT-3’; EcoRI site under-
lined) contained 22 nucleotides of the reverse stand of
the end of the 3’-UTR of the HBV genome and an
EcoRI restriction site (underlined) with an additional
one nucleotide to increase the efficiency of the clea-
vage by the restriction enzyme.
PCR amplification of the S gene
Primers MS-1 and MS-2 were used in a PCR reaction to
amplify the S gene and the 3’-UTR using the vector
pRc/CMV-HBs(S) as a template and the high fidelity
DNA polymerase Ex-Taq (Takara, Japan) as a polymer-
ase enzyme in a 50 μl volume reaction. Reaction mix-
tures were incubated in a programmable thermocylcer
Touchgene gradient PCR (Touchgene Gradient, USA)
using the following settings; initial denaturation: 2 min
at 94°C, 30 cycles of (denaturation step: 50 seconds at
94°C, annealing step: 50 seconds at 50°C, and extension
step: 2 min at 72°C) followed by final extension: 5 min
at 72°C. PCR products were subjected to agarose gel
electrophoresis in 0.8% wt/vol agarose gel and bands
were visualized by staining with ethidium bromide and
placing on a UV transilluminator.
Cloning of the S gene and the HBV-3’-UTR in rapid
cloning vector pCR2.1
In order to facilitate the restriction digestion and sub-
sequent cloning of the amplified PCR product, 2 μl of
the PCR product described above were ligated with 1
μl of the rapid cloning vector pCR2.1 (Invitrogen,
USA) in the presence of 1 × ligation buffer and 3 units
of T4 DNA ligase(promega, USA) at 16°C overnight.
Three μls of the ligation mixture were then electro-
plated into 50 μl electrocompetent E. coli using Gene-
pulser electroporator (Bio-Rad, USA) at 1.6 mV and 10
mm gap electroporator cuvette. Electroplated cells
were recovered in 350 μl SOC media [12] for 60 min
at 30°C with orbital shaking. Transformation mixtures
were then plated on LB plates supplemented with 25
μg/ml kanamycin and is 20 μg/ml 5-bromo-4-chloro-3-
indolyl-b-D-galactopyranoside (X-Gal). Plates were
incubated at 37°C overnight and white colonies were
then screened for the presence of the plasmid with the
right insert using colony PCR using the primers pair
AA437 (5’-AACAGCTATGACCATG-3’) and AA438
(5’-GTAAAACGACGGCCAGT-3’) that bind in the
pCR2.1 vector backbone in the regions flanking the
insert insertion site. The right plasmid was designated
pCR2.1-HBsAg(S).
Sub-cloning of the S gene and the HBV-3’-UTR in pRP265
The insert cloned in pCR2.1-HBsAg(S) as described
above was digested out using the restriction enzymes
KpnI and EcoRI (Promega, USA), gel purified, and
ligated into the expression vector pRP265 that was
restricted using the same enzymes, gel purified and trea-
ted with shrimp alkaline phosphatase (Promega, USA).
The ligation mixtures were then electroporated into
either E. coli DH5a or DB3.1. and plated on LB plates
supplemented with ampicillin at a final concentration of
100 μg/ml. As a negative control restricted pRP265
without insert ligation was also transformed into E. coli.
Ampicillin resistant E. coli were selected and screened
for the presence of the right insert. The vector contain-
ing the right insert was designated pRP-HBsAg(S)-GST.
Expression of the recombinant HBsAg(S) in E. coli
Cells carrying the pRP-HBsAg(S)-GST vector were
grown overnight in NB/Amp, containing 2% (wt/vol)
glucose to prevent any leaky expression of the recombi-
nant protein, with shaking at 37°C. In the next morning,
cells were sub-cultured in 50 ml of fresh medium
through 1:100 dilution and allowed to grow to mid-loga-
rithmic phase (~ 3 hours) at 37°C with shaking. When
the cultures reached an OD600 ~ 0.4, the expression of
the recombinant protein was induced by the addition of
Isopropyl b-D-1-thiogalactopyranoside (IPTG) in a final
concentration of 1 μM. Induction was continued for dif-
ferent time periods (0, 3, 6, and 24 hours) and at differ-
ent temperatures (30°C and 37°C) with shaking at 180
rpm. Aliquots were removed at different time points for
analysis using SDS-PAGE using standard protocols [12].
Solubilization of the inclusion bodies containing the
recombinant HBsAg(S)
In order to check if the recombinant HBsAg(S) is
included inside inclusion bodies a solubilization step
was performed. Briefly, induced bacterial cultures were
centrifuged at 3000 × g for 5 min at 4°C, pellets were
re-suspended in 1 ml lysis buffer (50 mM Tris HCl (pH
8), 10% glycerol, and 0.1% Triton X-100) and sonicated
on ice using a sonicator equipped with a microtip. Soni-
cation was carried out on ice for six 10 s bursts at 200-
300 W with a 10 s cooling period between each burst.
The cell debris and the potential inclusion bodies were
collected by centrifugation for 15 min at 10,000 × g at
4°C. The pellets were re-suspended into 1 volume of
solubilization buffer I (50 mM Tris HCl (pH 8.0), 1 mM
EDTA, 100 mM NaCl, and 8 M urea), and incubated for
60 min at room temperature. Then 9 volumes of solubi-
lization Buffer II (50 mM KH2PO4 (pH 10.7), 1 mM
EDTA, and 50 mM NaCl) were added and the mixture
was incubated for additional 30 min at room tempera-
ture. After solubilization, the pH was re-adjusted to 8
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with HCl and incubated for 30 min at room tempera-
ture. The un-dissolved inclusion bodies and cell debris
were collected by centrifugation for 5 min at 10,000 × g
at 4°C. The pellets were discarded and the supernatant
containing the solubilized inclusion bodies and the
recombinant HBsAg(S) was removed for SDS-PAGE
analysis and protein purification.
Refolding of the recombinant HBsAg(S)
In order to be able to purify the recombinant HBsAg(S)
released from the solubilized inclusion bodies, it needed
to be refolded so it can bind to the GST beads for puri-
fication. The refolding of the protein needed dialysis
against dialysis buffers (50 mM glycine, 10% glycerol, 5
mM mercaptoethanol, 50 mM Tris HCl (pH 8), 50 mM
NaCl, and 1 mM EDTA) containing decreasing concen-
trations of urea (4 M, 2 M,1 M, and 0 M) [12]. A final
dialysis run was carried out against the refolding buffer
diluted 1:3 with distilled water. The equilibrated protein
was then ready for affinity purification.
Purification of the recombinant HBsAg(S)
Dialyzed protein was mixed with 1/10 volume glu-
tathione sepharose beads slurry (Pierce, USA) with gen-
tle shaking for 1 h at room temperature. The mixture
was then packed into column and the flow through was
allowed to pass out of the column that was later washed
with five volumes PBS. To elute the bound protein, ali-
quots of a low pH elution buffer (0.1 M glycine HCl,
pH 2.7) were applied to the column and the collected
fractions were rapidly neutralized using 1/10 volume
neutralization buffer (2 M Tris, pH 8.0). Fractions col-
lected were analyzed qualitatively by measuring absor-
bance at 280 nm, and small aliquots of the fractions
with high readings were subjected to electrophoresis in
15% SDS-PAGE gel and stained with Coomassie blue
for visualization. The total volume of the purified pro-
tein solution was adjusted to 1.5 ml and quantitative
determination of the purified protein was determined
using the Bradford assay [12].
Statistical analyses
Statistical analyses were carried out by applying either
the Student t test or analysis of variance (ANOVA)
using GraphPad Prism software (GraphPad Software,
Inc., USA) where p values < 0.05 were considered statis-
tically significant.
Results
PCR amplification and cloning of the S gene
DNA primers MS-1 and MS-2 were used to amplify the
S gene of HBV together with the HBV-3’-UTR using the
pRc/CMV-HBs(S) as a template. The PCR reaction pro-
duced a single strong band of the expected size (i.e. ~ 2
kb) as shown in Figure 2A. The produced PCR product
was cloned into the rapid ligation vector pCR2.1 to pro-
duce the vector pCR2.1-HBsAg(S) (Figure 2B). Restric-
tion digestion of pCR2.1-HBsAg(S) with EcoRI and
KpnI resulted in the linearization of the pCR2.1 vector
and the release of the S gene-HBV-3’-UTR fragment
(Figure 2C). The later fragment was then gel purified
and ligated into the expression vector pRP265 that has
been digested with KpnI and EcoRI (Figure 3A &3B).
The resultant plasmid pRP-HBsAg(S)-GST (Figure 3C)
was digested with EcoRI and KpnI producing ~ 5 kb
band corresponding to linearized pRP265 vector and ~
2 kb band corresponding to the S gene-HBV-3’-UTR
insert (Figure 3D)
Expression and purification of HBsAg(S)-GST from E. coli
The fusion protein that is encoded by the vector pRP-
HBsAg(S)-GST (Figure 4A) consists of; (i) GST tag that
contains 219 amino acids (aa) with a predicted molecu-
lar weight of 25.59 kDa, (ii) polylinker consisting of 11
aa with a predicted molecular weight of 1.33 kDa, and
(iii) HBsAg(S) consisting of 226 aa with a predicted
molecular weight of 25.42 kDa. Adding the three frag-
ments makes the predicted molecular weight of the
fusion protein ~52.34 kDa.
E. coli strain harboring the vector pRP-HBsAg(S)-GST
was induced using IPTG to over-express the recombi-
nant fusion protein HBsAg(S)-GST. Induction of the
cells was followed by cell lysis through sonication,
Figure 2 Cloning of the HBV S gene and 3’-UTR in the rapid
cloning vector pCR2.1. (A) An image of an agarose gel showing
the MS-1-MS-2 PCR product. The * indicates the position of the PCR
product. (B) An image of an agarose gel showing the supercoiled
pCR2.1-HBsAg(S) and the * indicates the position of the plasmid. (C)
An image of an agarose gel showing the KpnI/EcoRI digestion
products of pCR2.1-HBsAg(S). The * indicates the position of the
linearized plasmid and the ** indicates the position of the dropped
insert. The left lane in each gel contains 1 kb DNA ladder (Promega,
USA); the sizes of the respective bands is indicated on the left side
of each panel.
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however upon running equivalent aliquots of the cyto-
plasmic lysates of both induced and un-induced cultures
in SDS-PAGE gel did not show any increase in the
abundance of a band around the expected size of the
HBsAg(S)-GST (~52 kDa) (Figure 4B). This meant that
the fusion protein HBsAg(S)-GST might not have been
expressed in these cells. However, it was observed that
the cells carrying pRP-HBsAg(S)-GST showed a lag in
growth in liquid culture when compared to the cells car-
rying the empty vector pRP265 and their colonies were
more sticky (data not shown). These observations sug-
gested that pRP-HBsAg(S)-GST is expressed inside the
cells, most probably in high concentrations, and the rea-
son that the protein is not detected in the cytoplasmic
lysates is that it might be included in inclusion bodies.
Inclusion bodies solubilization, followed by refolding
then affinity chromatography purification resulted in the
detection of the recombinant fusion protein HBsAg(S)-
GST. A band corresponding to the predicted size (~52
kDa) was obviously detected in the eluted proteins from
the GST column (Figure 4C). The detection of a single
prominent band in the SDS-PAGE gel indicates that the
purified protein is of high quality.
Effect of induction time and temperature on the protein
yield
Bacterial cultures of the cell carrying the expression vec-
tor pRP-HBsAg(S)-GST were induced for different time
intervals (3, 6, and 24 hours) and at different tempera-
tures (30 and 37°C). At each time point, the recombi-
nant protein was purified as described in the Materials
and Methods section and the protein content was
assayed using Bradford assay. When the cultures were
induced at 30°C, there was a gradual increase in the
amount of the purified protein however, the differences
between the three time points were statistically non-sig-
nificant (p value > 0.05) (Figure 5, white bars). On the
other hand, at 37°C, the highest amount of protein was
obtained after 3 hours of induction then there was slight
decrease in the recovered protein, but again the differ-
ences between the three time points were statistically
non-significant (p value > 0.05) (Figure 5, black bars).
The only significant difference was detected when com-
paring the amounts of the protein recovered after 6 hrs
where the protein recovered at 37°C was significantly
higher than that recovered after the same induction
time at 30°C with p value 0.019. Upon analyzing the two
variables (induction time and temperature) together via
ANOVA, only the temperature factor showed a signifi-
cant difference (p value < 0.0001). Extrapolating the
obtained yields in this small scale experiment, the
method described here will result in a protein yield of
approximately 140 μg protein per liter of culture.
Discussion
HBV infections are spreading worldwide and affecting a
substantial proportion of the world’s population [1,2].
The need for rapid and low cost reagents that can be
used for the detection and prevention of such infections
Figure 3 Sub-cloning of the HBV S gene and 3’-UTR in the
expression vector pRP265. (A) An image of an agarose gel
showing the supercoiled pRP265 and the * indicates the position of
the plasmid. (B) An image of an agarose gel showing the KpnI/
EcoRI digestion products of pRP265 and the * indicates the position
of the linearized plasmid. (C) An image of an agarose gel showing
the supercoiled pRP-HBsAg(S)-GST and the * indicates the position
of the plasmid. (D) An image of an agarose gel showing the KpnI/
EcoRI digestion products of pRP-HBsAg(S)-GST. The * indicates the
position of the linearized plasmid and the ** indicates the position
of the dropped insert. The left lane in each gel contains 1 kb DNA
ladder (Promega, USA); the sizes of the respective bands is indicated
on the left side of each panel.
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is highly urgent especially in the developing world where
healthcare resources are evidently scarce [13-15].
HBsAg is one of the major antigens of HBV that con-
stitutes a fundamental component in both diagnostic
and preventive tools for HBV. Initially the source for
such antigen was the plasma of high titer HBV carriers
however this approach suffered from safety issues in
addition to over-elaborate preparation process as well as
high cost of preparation.
Cloning and expression of HBsAg components have
been attempted many times. Attempts were carried on
using the yeast cells Saccharomyces cerevisiae as a host
[16,17] or in prokaryotic cells such as E. coli [18,19].
However, in all these early studies high levels of HBsAg
expression were not reported [20]. Going back and forth
between eukaryotic and prokaryotic systems several
groups reported success in the expression of HBsAg
with different advantages and disadvantages.
Expression in eukaryotic systems such as Saccharo-
myces cerevisiae, Pichia pastoris and insect expression
systems results in HBsAg proteins that are glycosylated
in different patterns and this glycosylation can affect the
Figure 4 Expression and purification of the HBsAg(S)-GST fusion protein. (A) Schematic diagram showing the DNA region cloned in pRP-
HBsAg(S)-GST and the sizes of the predicted encoded protein. The map in this figure was generated using the BioEdit software (Ibis Biosciences,
USA). (B) An image of a Coomassie blue-stained SDS-PAGE gel of cell lysates of E. coli strains carrying the pRP-HBsAg(S)-GST that were either not
induced with IPTG (-) or induced with 1 mM IPTG for 3 hours (+). The first lane contained protein molecular weight marker (BioRad, USA) and
the sizes of the respective bands is indicated on the left side of the panel. (C) An image of a Coomassie blue-stained SDS-PAGE gel of purified
HBsAg(S)-GST fusion protein. The first lane contained protein molecular weight marker (Fermentas, USA) and the sizes of the respective bands is
indicated on the left side of the panel. Lane 2 contained a sample of the column flow through (FT), lane 3 contained a sample of the column
wash (W), while lanes 5-8 contain samples of the fractions eluted from the GST column. The arrow indicates the position of the main
component eluted from the column with a band size of approximately 52 kDa.
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immunoreactivity of the product [5]. In this respect the
Pichia pastoris is better than Saccharomyces cerevisiae
in that proteins synthesized by Pichia pastoris may
resemble the glycoprotein structure of higher eukaryotes
[21] as the length of the oligosaccharide chains added
post-translationally to proteins in Pichia is much shorter
than that in Saccharomyces cerevisiae [22]. Other advan-
tages of a system such as Pichia pastoris are the high
level and stability of the protein expression and easy
manipulation [5].
Prokaryotic systems in general and E. coli in particu-
lar, have the great advantages of low cost, easy manip-
ulation, high level of expression of recombinant
proteins. With the E. coli being capable of achieving
about five times typical specific product formation rate
[mg·g-1·h-1] of recombinant proteins that are expressed
cytoplasmically as compared to Pichia pastoris and
about 25% more increase in volumetric productivity
[mg·L1·h1] [23]. In addition, there is a high rate of
development in metabolic engineering strategies and
tools that are looking into approaches to reveal meta-
bolic bottle-necks in prokaryotic host cells. This pro-
gress makes a potentially sweet future for
glycoengineering in E. coli for the production of
human therapeutic drugs [24].
The purification process of the HBsAg from Saccharo-
myces cerevisiae described by Kobayashi et. al. [7] is
long, complicated, and costly due to the use of immu-
noaffinity chromatography using antibodies for hepatitis
B surface antigen bound to sepharose. Using fusion
proteins such as poly histidine or GST followed by
metal ion affinity chromatography promotes efficient
recovery and purity of recombinant protein from crude
cell extracts [5]. Different fragments of the HBsAg com-
plex have been purified as a fusion protein with b-galac-
tosidase [19], b-lactamase [25], or hexa-histidine [5]. To
the best of our knowledge this is the first report of the
expression of a GST fusion of the HBsAg(S) fragment
which represents the major antigen of HBV. Using GST
as a fusion tag has several advantages such as providing
a higher degree of purification in a single chromato-
graphic step, increased solubility of the recombinant
protein, non-interference with the structure and func-
tion of the recombinant protein, providing immunogenic
as well as biochemical assay of the recombinant protein,
easy elution steps, and ease of cleavage and removal of
the affinity tag [26].
The fusion protein was expressed in E. coli and
despite the fact that GST usually increases the solubility
of the fusion protein; the GST-HBsAg(S) fusion was
included into inclusion bodies rather than being free in
the cytoplasm. This required an extra step of inclusion
bodies solubilization followed by dialysis to refold the
recombinant protein. Despite this the protocol described
here is simpler, faster, costs less than the one described
by Kobayashi et. al, [7]. In addition the refolding can be
achieved using other protocols as those described [12]
leading to more time savings.
The protein yields obtained in the small scale experi-
ments described in this study are very encouraging that
high yields could be obtained upon applying large scale
production. Determination of the immunogenicity (as
vaccine candidate) or the sensitivity, specificity, accuracy
and linearity (as a diagnostic immunoassay component)
of the purified GST-HBsAg(S) is still required to prove
the usefulness of the application of this product in
developing countries such as Egypt.
Conclusions
The construct and the method described in this study
represent an attractive alternative to previously
described protocols for the production and purification
of HBsAg especially for countries of limited resources.
The described protocol is characterized with the simpli-
city, low cost and high productivity.
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